Angiographic embolization for XXXX : low mortality, high morbidity.

@entity1 @entity548 @entity1157 @entity1320 @entity99 @entity130
OBJECTIVE: Angiographic embolization (AE) is a safe and effective method for controlling @entity548 in both blunt and penetrating @entity99 . Improved survival after @entity99 has been documented using a multimodality approach; however, @entity1 still have significant long-term morbidity. This study examines further the role of AE in both blunt and penetrating @entity99 and the outcomes of its use. METHODS: The medical records of 37 consecutive @entity1 admitted from 1995 to 2002 to a Level I @entity130 center who underwent hepatic angiography with the intent to embolize were reviewed. Demographic and clinical information including Injury Severity Score, length of stay, mortality, intra-abdominal complications, admission physiologic variables, and the number and type of abdominal operations performed were collected. RESULTS: Thirty-seven @entity1 underwent hepatic angiography and 26 @entity1 had @entity99 performed. Eleven @entity1 underwent early-AE, immediately after computed tomographic scanning, and 15 underwent late-AE, after liver-related operations or later in their hospital course. There was a 27% mortality rate overall. There were 11 liver-related complications in the 26 embolizations. Excluding the early deaths, the associated morbidity was 58%, which included @entity99 , @entity99 , and @entity1157 . CONCLUSION: There is increasing adjunctive use of AE in @entity1 managed both operatively and nonoperatively. @entity1320 are common in these salvaged @entity1 with severe @entity99 . Those @entity1 that underwent early-AE received significantly fewer blood transfusions and more commonly had sterile hepatic collections. Only 26% of @entity1 required liver-related surgery after AE. Therefore, the integration of AE as an adjunctive modality for @entity1 with high-grade @entity99 is a safe and effective therapeutic option.
